Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
A new study has found that subsidies for prescription drugs can improve the use of adjuvant therapy in women with early-stage breast cancer and help reduce disparities in the use of these proven treatments among black and Hispanic women.
-
Scientists have designed a device that measures the mass of single cancer cells to predict how cells respond to drug treatment. The technology could potentially help clinicians determine whether a drug effectively kills cancer cells.
-
Dr. Julia Rowland, director of NCI’s Office of Cancer Survivorship, on the office’s 20th anniversary and efforts to ensure continued progress in survivorship research and improve survivors’ lives.
-
The FDA has approved atezolizumab and expanded the approval of pembrolizumab for some patients with non-small cell lung cancer.
-
A new report from the President’s Cancer Panel outlines how connective technologies can promote cancer prevention, enhance patients’ treatment experience, and accelerate progress in cancer research.
-
Updated CDC recommendations advise those younger than age 15 need only two doses of the HPV vaccine instead of three.
-
An NCI Cancer Currents blog post about the NCI Global Cancer Research Symposium, which examined ways of increasing research collaboration, particularly in cancer prevention and screening, to reduce the cancer burden.
-
The Food and Drug Administration (FDA) has granted accelerated approval to olaratumab (Lartruvo®) for the treatment of some patients with soft tissue sarcoma.
-
Findings from a new study from NCI researchers could help predict whether a tumor will respond to a new class of promising cancer drugs, and identifies a potential way to overcome that resistance.
-
A new study has identified a potentially critical vulnerability in lung cancers that have mutations in the KRAS gene, and showed that a drug already under study may be able to exploit it.